BCM
FLNA

Bluefin Capital Management’s Filana Therapeutics FLNA Stock Holding History

Bluefin Capital Management’s Portfolio FLNA Stock Details FLNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-17,977
Closed -$410K – 268
2023
Q4 		$410K Buy
+17,977
New +$380K 0.04% 81

Other funds holding FLNA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GCM
Gallacher Capital Management Lone Tree, Colorado $178M AUM 29.29% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Bluefin Capital Management's FLNA Position: Q1 2024 in Review

Bluefin Capital Management sold out of Filana Therapeutics (FLNA) in Q1 2024, closing a stake of 17,977 shares — an estimated $410K sold.

Bluefin Capital Management first reported a position in FLNA in Q4 2023 and held it in 1 quarter. The position peaked at $410K in Q4 2023. 143 funds tracked by Wall St. Rank hold FLNA as of Q1 2024.

  • Bluefin Capital Management reported no remaining Filana Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Bluefin Capital Management sold 17,977 Filana Therapeutics shares in Q1 2024, an estimated $410K.
  • Bluefin Capital Management first reported a position in Filana Therapeutics in Q4 2023 and held it in 1 quarter.
  • Bluefin Capital Management's Filana Therapeutics position peaked at $410K in Q4 2023.
  • 143 funds tracked by Wall St. Rank held Filana Therapeutics as of Q1 2024.

Based on Bluefin Capital Management's 13F filing for Q1 2024, filed 15 May 2024.